placebo + scopolamine

placebo + scopolamine refers to a specific pharmacological combination used as a control and challenge agent in clinical research conducted by Merck Sharp & MSD, particularly in the context of Alzheimer's disease. This combination consists of a placebo (formulated to match active investigational drugs such as MK-3134 and donepezil) and scopolamine, a small molecule muscarinic acetylcholine receptor antagonist. Scopolamine is utilized to induce temporary cognitive, memory, and attention deficits in healthy volunteers, effectively mimicking the cholinergic deficit observed in Alzheimer's disease. This scopolamine challenge model provides a baseline of induced impairment, allowing researchers to evaluate the potential of new therapeutic candidates to reverse these deficits compared to a negative control arm.

Other names

Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg